Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
9 stopped studies mapped to HER2-Negative Breast Carcinoma and descendants · 100% state a reason
Over the 9 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06671912 | Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial(LoTam) | Phase 3 | suspended | Nov 4, 2024 | Alliance for Clinical Trials in Oncology | Amending protocol to increase sample size | Other (stated, no rule matched) |
| NCT07136493 | Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With… | N/A | withdrawn | Aug 22, 2025 | City of Hope Medical Center | Funding This study has been closed at City of Hope at the request of the Sponsor due to delays and… | Funding |
| NCT05488145 | A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer… | N/A | terminated | Aug 4, 2022 | Emory University | Insufficient Staff | Other (stated, no rule matched) |
| NCT05554354 | Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in… | Phase 2 | terminated | Sep 26, 2022 | National Cancer Institute (NCI) | Other - slow accrual | Enrollment / accrual |
| NCT06590558 | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a… | Phase 1 | withdrawn | Sep 19, 2024 | National Cancer Institute (NCI) | Manually added per CS0177524- Weekly CTEP status report. | Other (stated, no rule matched) |
| NCT05967286 | Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment… | Phase 2 | withdrawn | Aug 1, 2023 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT04756505 | Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of… | Phase 1 | withdrawn | Feb 16, 2021 | M.D. Anderson Cancer Center | Per Sponsor Request-no longer manufacturing the study drug | Drug supply |
| NCT05244434 | Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With… | N/A | withdrawn | Feb 17, 2022 | City of Hope Medical Center | PI withdrawn | Other (stated, no rule matched) |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic… | Phase 1 | withdrawn | Aug 4, 2020 | Pamela Munster | Funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Sep 2, 2026source: clinicaltrials